Respiratory tract infection and risk of bleeding in oral anticoagulant users: self-controlled case series
- PMID: 34933893
- PMCID: PMC8689396
- DOI: 10.1136/bmj-2021-068037
Respiratory tract infection and risk of bleeding in oral anticoagulant users: self-controlled case series
Abstract
Objective: To estimate the association between untreated, community acquired, respiratory tract infections and bleeding in oral anticoagulant users.
Design: Self-controlled case series.
Setting: General practices in England contributing data to the Clinical Practice Research Datalink GOLD.
Participants: 1208 adult users of warfarin or direct oral anticoagulants with a general practice or hospital admission record of a bleeding event between January 2010 and December 2019, and a general practice record of a consultation for a community acquired respiratory tract infection for which immediate antibiotics were not prescribed (that is, untreated).
Main outcome measures: Relative incidence of major bleeding and clinically relevant non-major bleeding in the 0-14 days after an untreated respiratory tract infection, compared to unexposed time periods.
Results: Of 1208 study participants, 58% (n=701) were male, median age at time of first bleed was 79 years (interquartile range 72-85), with a median observation period of 2.4 years (interquartile range 1.3-3.8). 292 major bleeds occurred during unexposed time periods and 41 in the 0-14 days after consultation for a respiratory tract infection. 1003 clinically relevant non-major bleeds occurred during unexposed time periods and 81 in the 0-14 days after consultation for a respiratory tract infection. After adjustment for age, season, and calendar year, the relative incidence of major bleeding (incidence rate ratio 2.68, 95% confidence interval 1.83 to 3.93) and clinically relevant non-major bleeding (2.32, 1.82 to 2.94) increased in the 0-14 days after an untreated respiratory tract infection. Findings were robust to several sensitivity analyses and did not differ by sex or type of oral anticoagulant.
Conclusions: This study observed a greater than twofold increase in the risk of bleeding during the 0-14 days after an untreated respiratory tract infection. These findings have potential implications for how patients and clinicians manage oral anticoagulant use during an acute intercurrent illness and warrant further investigation into the potential risks and how they might be mitigated.
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/disclosure-of-interest/ and declare: support from the Health and Care Research Wales for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work.
Figures
Similar articles
-
Risk of bleeding amongst warfarin and direct oral anticoagulant users prescribed immediate antibiotics for respiratory tract infection: Cohort study.Pharmacoepidemiol Drug Saf. 2024 May;33(5):e5794. doi: 10.1002/pds.5794. Pharmacoepidemiol Drug Saf. 2024. PMID: 38680080
-
Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care.BMJ. 2018 Jul 4;362:k2505. doi: 10.1136/bmj.k2505. BMJ. 2018. PMID: 29973392 Free PMC article.
-
A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants.Eur Heart J Cardiovasc Pharmacother. 2017 Jan;3(1):28-36. doi: 10.1093/ehjcvp/pvw031. Epub 2016 Sep 27. Eur Heart J Cardiovasc Pharmacother. 2017. PMID: 27680880 Free PMC article.
-
Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis.J Am Heart Assoc. 2017 Jul 18;6(7):e005835. doi: 10.1161/JAHA.117.005835. J Am Heart Assoc. 2017. PMID: 28720644 Free PMC article. Review.
-
Management of haemorrhagic complications associated with oral anticoagulant treatment.Expert Opin Drug Saf. 2002 Jul;1(2):129-36. doi: 10.1517/14740338.1.2.129. Expert Opin Drug Saf. 2002. PMID: 12904147 Review.
Cited by
-
Limaprost and the Risk of Bleeding: A Self-Controlled Case Series Study.Neurospine. 2023 Dec;20(4):1490-1500. doi: 10.14245/ns.2346640.320. Epub 2023 Dec 31. Neurospine. 2023. PMID: 38171315 Free PMC article.
-
Rivaroxaban Plasma Concentration and Clinical Outcomes on Older Patients with Non-valvular Atrial Fibrillation and Pulmonary Infection.Am J Cardiovasc Drugs. 2024 Jan;24(1):129-139. doi: 10.1007/s40256-023-00622-4. Epub 2023 Dec 24. Am J Cardiovasc Drugs. 2024. PMID: 38142441
References
-
- National Institute for Health and Care Excellence. Anticoagulants, including non-vitamin K antagonist oral anticoagulants (NOACs). 2018. https://www.nice.org.uk/advice/ktt16/chapter/Evidence-context
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical